Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 ORR and PFSR 24 rates by dose in patients with melanoma, NSCLC, and RCC treated with nivolumab monotherapy

From: Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

  MEL (N = 107) NSCLC (N = 129) RCC (N = 34)
Dose (mg/kg) ORR % (n/N) PFSR 24, % ORR % (n/N) PFSR 24, % ORR % (n/N) PFSR 24, %
0.1 35 (6/17) 41
0.3 28 (5/18) 35
1 31 (11/35) 51 3 (1/33) 26 28 (5/18) 50
3 41 (7/17) 55 24 (9/37) 40
10 20 (4/20) 35 20 (12/59) 33 31 (5/16) 67
  1. — = not tested, MEL melanoma, NSCLC non-small cell lung cancer, ORR objective response rate, PFSR 24 progression-free survival rate at 24 weeks, RCC renal cell carcinoma